Q2 Clinical Intake: Only 14 Protocol Slots Remaining. Approvals subject to biometrics.
XORIS · Synthetic Small-Molecule

Metabolic Dominance.
Without the Pen.

Outsmart biological fatigue. XORIS, our next-generation oral GLP-1 tablet, delivers clinical-grade systemic exposure with zero needles, zero morning fasting rules, and absolute logistical freedom.

Currently on a first-gen oral GLP-1?

One Tablet.

24-Hour Sustained Activation

Board-Certified Oversight
Cold-Chain Independent
Financial & Biological ROI

The Architecture of Advantage

Why pay a ₱200,000+ premium every year for logistical nightmares? Compare the old-world biological injectables against our synthetic oral technology.

The Pen

Old-Gen Biologicals
  • Subcutaneous puncture required weekly.
  • Strict refrigeration. Ruins travel flexibility.
  • Plagued by global supply-chain shortages.

Annual Sunk Cost

~₱360,000/yr

The Pill

PEPTOLOGY Architecture
  • 100% Zero-needle synthetic oral tablet.
  • Room-temp stable. Absolute travel freedom.
  • Flat-rate scaling. Predictable protocol economics.

Protocol Annual Investment

₱150,000/yr

Save ₱210,000+

Systemic Biology

How The Architecture Works

Click the biological nodes below to understand how the small-molecule overrides your current metabolic baseline across three distinct systems.

Neurological Center

Hypothalamus Target

The Consumer Experience: The constant internal monologue obsessing over food—known as "food noise"—is completely silenced. You simply forget to be hungry.

Clinical Pharmacodynamics

The small-molecule crosses the blood-brain barrier to bind with central GLP-1 receptors, aggressively down-regulating appetite-stimulating neuropeptides (NPY/AgRP) and up-regulating satiety signals (POMC/CART).

Gastric Architecture

Digestion Delay

The Consumer Experience: You eat a fraction of your normal portion and feel physically full for hours. This is why you must obey the "70% Gastric Limit" rule to avoid nausea.

Clinical Pharmacodynamics

Activation of local vagal afferent nerves causes a profound deceleration of gastric emptying. This mechanical delay prolongs postprandial distension, sending secondary vagal fullness signals back to the hindbrain.

Pancreatic Engine

Beta-Cell Regulation

The Consumer Experience: You stop crashing after meals. Your energy levels remain perfectly stable throughout the day because your body is finally managing sugar correctly.

Clinical Pharmacodynamics

Induces glucose-dependent insulin secretion while simultaneously suppressing inappropriate glucagon release. This lowers fasting glucose and dramatically reduces systemic, low-grade inflammation (hsCRP).

Pharmacokinetic Stability

Eliminate the "Day-5 Crash."

Weekly injectables peak violently and crash by Day 5, causing massive spikes in hunger and mood swings. The daily Oral Architecture builds a flawless, flat-line steady state.

Old Injectables (Peaks & Crashes)
PEPTOLOGY Daily Pill (Steady State)
Toxic Peak Therapeutic Zone Hunger Returns
Week 1 Steady State
Interactive AI Projector

Calculate Your Biological & Financial ROI.

Dial in your current metrics. The system dynamically projects your exact clinical weight loss targets (based on Phase 3 data) and calculates your hard cash savings versus injectables.

95kg
170cm
₱30k

12-Month Bio Target

83.2 kg

Based on Phase 3 mean reduction (-12.4%) at steady-state Apex dose.

12-Month Net Savings

₱210k

Extra cash retained by switching from injectables to the ₱12,500 flat-rate pill.

Protocol Economics Optimized
Clinical Expectations

The 90-Day Trajectory

True metabolic correction is not overnight. Understand the precise biological milestones your body will execute as we titrate your dosage.

Weeks 1 - 4

Neurological Override

The 1mg Primer dose engages brain receptors. Prospective hunger drops immediately. You will notice a profound silence in "food noise" and cravings.

Weeks 5 - 8

The Gastric Adaptation

Dose escalates to 3mg. Digestion significantly slows. The "70% Gastric Limit" rule becomes biologically enforced. Overeating becomes physically uncomfortable.

Weeks 9 - 12+

Systemic Dominance

Dose hits the 6mg+ Apex. The body enters peak lipolysis (fat burning). Systemic inflammation (hsCRP) drops by up to 50%. You are locked into the new baseline.

The 70% Contract

This protocol is a biological tool, not magic. It radically slows gastric emptying. To succeed, you must mentally commit to evolving your behavior.

The Gastric Limit You must stop eating when you feel 70% full. Overeating past this point will reliably cause physical distress, as your stomach lacks capacity for excess volume.
Never Split the Pill The tablet is precision-formulated. Swallow it intact. Splitting destroys the delivery architecture and instantly ruins the pharmacokinetic dose.

Clinical Efficacy Requires Discipline.

We provide the pharmaceutical architecture. You provide the behavioral compliance. Together, this combination delivers up to a 12.4% average body weight reduction.

Client Intel

Real-World Efficacy.

Data tells. Results sell. These are the operational realities of transitioning from older biological therapies to the PEPTOLOGY Architecture.

Transitioned from Tirzepatide 15mg

"I hit my target weight but hated the cold-chain logistics for travel. Transitioned to the daily pill 3 months ago. Maintained my 68kg baseline perfectly. Zero morning nausea. The operational freedom is unmatched."

Anonymous Client

Makati, PH

Transitioned from Semaglutide Pens

"I was paying ₱30k a month for pens and constantly stressing over supply shortages. Switched to this oral architecture. Down 8kg in 12 weeks, saved a ton of cash, and my digestion adapted perfectly."

Anonymous Client

BGC, Taguig

Simple Protocol Economics.

Stop paying more when your dose goes up. We utilize a flat-rate subscription. Your clinical dose scales up automatically—your price never changes.

Protocol Membership

Billed every 4 weeks. Cancel anytime.

₱12,500 /mo
  • All doses included (1mg to 36mg)
  • Automated step-up shipments
  • Ongoing medical clearance
Highest Biological ROI

The 90-Day Reset

Pre-pay the first 3 cycles. Save 15%.

₱31,800 /90 days
  • Locks in Primer, Activation & Apex doses
  • Guarantees 90-day supply continuity
  • Saves ₱5,700 versus monthly

Clinical Rationale

Why we built the Oral Architecture

"For years, I watched elite clients struggle with biological injectables. Not because the medicine didn't work, but because the logistics were a nightmare. Peptides are incredibly fragile. One broken cold-chain during shipping, one missed refrigeration window while traveling, and a ₱30,000 pen becomes useless water."

"We needed a solution that survived the real world. By utilizing a synthetic small-molecule structure instead of a fragile peptide, we engineered a GLP-1 that survives stomach acid without needing complex absorption enhancers. It absorbs directly, acts systemically, and stays stable in your briefcase."

"This isn't just about avoiding needles. It is about operational freedom. We removed the friction, so your body can finally focus on metabolic dominance."

Asymmetric Intelligence.

Choose your perspective. We provide operational answers for patients, and raw pharmacokinetic data for clinicians.

I am currently on injections. How do I switch?
This is our most common scenario. If you have reached your target weight using Tirzepatide or Semaglutide, you cannot simply stop cold turkey without risking massive weight regain. You transition to our Oral GLP-1 as an "Off-Ramp" maintenance protocol. It sustains your metabolic correction seamlessly.
Do I have to take it exactly at the same time every day?
While biological consistency is preferred, the architecture is highly forgiving. Because it builds a long-acting steady state in your blood, you have a wide window. You do not have to fast in the morning. Just take it with any meal that fits your operational schedule.
What exactly happens if I ignore the 70% limit and overeat?
The medication paralyzes the rate at which your stomach empties food into your intestines. If you eat a large volume or highly greasy foods, the food physically has nowhere to go. Your body will reliably reject it via severe nausea or vomiting. The limit is a biological law, not a suggestion.

Notice to Prescribers: This section contains unredacted Phase 2/3 pharmacokinetic data for clinical evaluation.

How does it bypass gastric degradation without SNAC?
Unlike first-generation oral GLP-1s, which rely on an absorption enhancer to shield a fragile peptide, XORIS utilizes a non-peptide small molecule. It inherently resists proteolytic cleavage in the stomach, allowing for rapid systemic exposure without morning water/fasting constraints.
What is the pharmacokinetic half-life?
The steady-state half-life is profoundly robust, ranging from 28.7 to 67.5 hours. Mathematical modeling confirms that a once-daily dosing protocol maintains circulating serum levels perfectly above the therapeutic threshold, negating the steep peaks and troughs associated with short-acting injectables.
Is this a mono-agonist or dual-agonist?
It is a potent, highly selective mono-agonist targeting solely the GLP-1 receptor. It intentionally biases away from β-arrestin recruitment. This partial agonism prevents rapid receptor internalization and desensitization, allowing the medicine to maintain long-term clinical efficacy without demanding constant dose escalations.